|For Immediate Release|
|Tuesday, May 3, 2004|
LAWRENCE LIVERMORE NATIONAL LABORATORY BEGINS USING BIOLOG PHENOTYPE MICROARRAY TECHNOLOGY IN GENOMIC RESEARCH
Hayward , CA - May 3, 2004 - Biolog, Inc. announced today that its new Phenotype MicroArray™ (PM) technology has been installed under a collaborative agreement and begun to be used at Lawrence Livermore National Laboratory (LLNL) to complement other high-throughput research on pathogens of interest to Civilian Biodefense.
Phenotype MicroArrays represent a fundamental technology platform, which allows scientists to easily and efficiently test hundreds to thousands of cellular traits simultaneously. The technology has the promise of determining cellular phenotypic expression in many areas of research. The two most important near term applications are using PMs to determine the effect of genetic changes on cells and to determine the effect of drugs on cells.
The LLNL researchers will use the PM technology to understand and characterize phenotypes of different strains of bacteria, specifically focused on Yersinia pestis, Bacillus anthracis, and other pathogenic organisms that are potential bioterrorist agents. The phenotypic data derived from these experiments will be interpreted in conjunction with comparative proteomic and genomic experiments at Lawrence Livermore National Laboratory.
Biolog, Inc. is demonstrating that PM phenotypic data alone can provide invaluable information about how and where genes are expressing themselves in this cell line. The company’s goal is to link the PM results to gene expression data, and efficiently identify how genes are regulating various cellular pathways.
Biolog has installed their proprietary OmniLog® System for high-throughput kinetic analysis of the PM panels at LLNL. The Phenotype MicroArray panels are sets of approximately 2,000 cellular assays that enable comparative analyses of a variety of metabolic and drug sensitivity changes in cells. LLNL will initially be testing bacterial strains. Mutant strains will be analyzed for phenotypic changes using the PM technology and results will then be compared to the phenotypes of the normal cell line.
Biolog has an active technology-placement program to use the current generation of PMs for research using bacterial and fungal model cell lines. The company is developing similar arrays for use with mammalian cell lines.
The work at Lawrence Livermore National Laboratory, funded by the U.S. Department of Homeland Security, aims to develop the next-generation biological and chemical detectors to provide real-time monitoring for BT events. For instance, Yersinia pestis, the etiological agent of plague, and Bacillus anthracis, the etiological agent of anthrax, are on the U.S. Centers for Disease Control biothreat list, and better characterization of these agents will benefit detection efforts.Biolog, a privately held company based in Hayward , CA , is a pioneer in the development of powerful new cell analysis tools for solving critical problems in clinical, pharmaceutical, and biotechnology research and development. The company’s Phenotype MicroArray technology and OmniLog® PM System can be used in the discovery and development of new drugs as well as bioactive agents for animal and plant applications. Further information can be obtained at the company’s website, www.biolog.com.